Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945237 | 1.00 | PFKFB3 (0.41) | PFKFB3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29217890 | 0.85 | KIF11 (0.42) | KDM1AKIF11CCR2CA1CA2 | |
| SCHEMBL4194854 | 0.82 | DDR1 (0.46) | PFKFB3KDM1ATRPV4CCR2CA1 | |
| SCHEMBL14100608 | 0.81 | PFKFB3 (0.41) | PFKFB3KDM1ATRPV4CA1CA2 | |
| SCHEMBL1541130 | 0.81 | CA2 (0.53) | PFKFB3KDM1AABCB11TRPV4KIF11 | |
| SCHEMBL29744331 | 0.81 | CA2 (0.53) | PFKFB3KDM1AABCB11TRPV4KIF11 | |
| SCHEMBL695564 | 0.81 | TRPV4 (0.58) | PFKFB3KDM1ATRPV4CA1CA2 | |
| SCHEMBL10296146 | 0.81 | PFKFB3 (0.41) | PFKFB3KDM1ATRPV4CA1CA2 | |
| SCHEMBL29843259 | 0.81 | TRPV4 (0.58) | PFKFB3KDM1ATRPV4CA1CA2 | |
| SCHEMBL28766850 | 0.81 | CCR2 (0.41) | CCR2CA1CA2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-2951169-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-28 | — | — | EP | disclosed |
| CN-106573921-B | Imidazolidine-2, 4-dione derivatives | 博福-益普生（天津）制药有限公司 | 2019-05-07 | — | — | CN | disclosed |
| EP-3089974-B1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2019-02-20 | — | — | EP | disclosed |
| CN-105849101-B | New imidazolidine -2,4- derovatives | 益普生制药股份有限公司 | 2019-02-19 | — | — | CN | disclosed |
| EP-3089975-B1 | NOVEL IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2018-06-06 | — | — | EP | disclosed |
| US-9975880-B2 | Imidazolidine-2,4-dione dervatives | IPSEN PHARMA S.A.S. (FR) | 2018-05-22 | — | — | US | disclosed |
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9926333-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-27 | — | — | US | disclosed |
| US-20170327514-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| CN-1411453-A | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-04-16 | — | — | CN | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | PFKFB3 43/4885PIK3CD 1055/4885PIK3CA 997/4885 |
| US-20170327514-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | PFKFB3 2985/4885PIK3CD 758/4885PIK3CA 283/4885 |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | PFKFB3 3736/4885PIK3CD 3509/4885PIK3CA 2682/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | PFKFB3 43/4885PIK3CD 925/4885PIK3CA 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.